Abstract
Melanoma incidence is consistently rising as well as the detection of early prognostically favourable tumours. However, the number of advanced tumours with high risk of further progression is not decreasing.
Adjuvant therapy with IFN alfa prolongs disease free survival in some patients but has only limited effect on prolongation of the overall survival.